Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs
Publication Date Apr 2017
Product Type Report
Single User License help $ 4995.00
Site User License help $ 9990.00
Corporate User License help $ 14985.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability.

The chronic nature of the disease, which requires ongoing treatment, and the relatively high annual cost of therapy (ACoT) have made RA treatment a highly lucrative market.

The RA therapeutic market has become very competitive due to the high number of new drug approvals. Competition is fierce, particularly among TNF-α inhibitors, which dominate the treatment market for RA patients who are refractory to traditional disease-modifying anti-rheumatic drugs (DMARD). Despite this, 30% of RA patients fail to attain a clinical response when treated with TNF-α inhibitors. However, other targeted programs, as well as newly marketed small-molecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNF-α inhibitors. Recently published study results of Xeljanz have shown a significant reduction in the risk of developing cardiac diseases such as heart attack and stroke in patients with RA.

Despite the superior efficacy of recently marketed therapies over traditional DMARD therapies, there is a need to improve safety in the therapeutic landscape. Elevated rates of infection are a frequent consequence of the immunosuppression involved in treatments, but this is required to suppress the autoimmune responses responsible for the symptoms of the condition. As a result, these biological therapies are not recommended to patients who are susceptible to infection.

In addition, there is a need to create biologics with more convenient and less invasive drug-delivery methods, as all existing therapies are administered subcutaneously or intravenously. These routes of administration are frequently associated with pain, rash, and allergic reactions at the injection or infusion site, and in the case of infusion flu-like illness, fever, chills, nausea, and headache. Therefore convenient and safe administration without significant compromise of therapy efficacy remains an unmet need.

Although the recently approved drug Xeljanz is an orally administered small-molecule drug, indicated as a second-line treatment for RA patients who have not shown an adequate response to methotrexate, and as a third-line therapy for patients who have not responded sufficiently to biologics, it carries a black-box warning in the US due to the safety issues of serious infections and malignancy.
Scope

    The current South-East Asia RA market contains novel products, including Xeljanz, a JAK inhibitor; and Actemra (tocilizumab), an IL-6 receptor inhibitor.

    What are the competitive advantages of the existing novel drugs?

    There are over 450 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.

    Which classes of novel drugs are most prominent in the pipeline?

    What is the potential for pipeline products to address unmet needs in the RA market?

    Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.

    How do failure rates vary by stage of development, molecule type, and molecular target?

    How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

    Over the 2015–2022 forecast period, the South-East Asia RA therapeutics market is expected to increase in value at a CAGR of 4.7%, from $1.04 billion to over $1.4 billion.

    Which markets make the most significant contribution to the current market size?

    What are the epidemiology trends in these markets?

    Will new market entrants lead to substantial changes in annual therapy costs?

    How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?

    Rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.

    Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons To Buy

    This report will enable you to:

    Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.

    Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.

    Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.

    Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.

    Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.

    Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.

    Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.


Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 8

2 Introduction 10

2.1 Disease Introduction 10

2.2 Epidemiology 11

2.3 Symptoms 11

2.4 Etiology and Pathophysiology 11

2.5 Diagnosis 13

2.5.1 Physical Examination 13

2.5.2 Blood Tests 13

2.5.3 1987 Rheumatoid Arthritis Classification 14

2.5.4 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis 14

2.6 Prognosis 14

2.7 Treatment Guidelines and Options 15

2.7.1 Pharmacological 16

2.7.2 Methotrexate 16

2.7.3 Hydroxychloroquine 17

2.7.4 Leflunomide 17

2.7.5 Sulfasalazine 17

2.7.6 Cyclosporine 17

2.7.7 Xeljanz (tofacitinib) 17

2.7.8 Other Non-biologics 18

2.7.9 Biologic Disease-Modifying Anti-rheumatic Drugs 18

2.7.10 Disease Scoring Methods for Measuring Treatment Efficacy 19

2.8 Co-infection or Co-morbidities 20

3 Marketed Products 21

3.1 Overview 21

3.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs 21

3.2.1 Methotrexate-Based Products 21

3.2.2 Xeljanz (tofacitinib) – Pfizer 22

3.3 Biologic Disease-Modifying Anti-rheumatic Drugs 23

3.3.1 Infliximab 23

3.3.2 Humira (adalimumab) – AbbVie 24

3.3.3 Etanercept 24

3.3.4 Rituximab 25

3.3.5 Orencia (abatacept) – Bristol-Myers Squibb 26

3.3.6 Simponi (golimumab) – Johnson & Johnson, Merck 26

3.3.7 Cimzia (certolizumab pegol) – UCB 27

3.3.8 Actemra (tocilizumab) – Roche 27

3.4 Comparative Efficacy and Safety of Marketed Products 28

4 Pipeline Analysis 34

4.1 Overview 34

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 34

4.3 Pipeline by Molecular Target 36

4.4 Promising Pipeline Candidates 39

4.4.1 Baricitinib – Eli Lilly 39

4.4.2 Sarilumab – Regeneron/Sanofi 41

4.4.3 Sirukumab – Johnson & Johnson 43

4.4.4 Peficitinib – Astellas 44

4.4.5 Upadacitinib – AbbVie 46

4.4.6 Filgotinib – Galapagos 47

4.5 Comparative Efficacy and Safety of Pipeline Products 48

4.6 Product Competitiveness Framework 50

5 Clinical Trial Analysis 52

5.1 Failure Rate 52

5.1.1 Overall Failure Rate 52

5.1.2 Failure Rate by Phase and Molecule Type 54

5.1.3 Failure Rate by Phase and Molecular Target 55

5.2 Clinical Trial Duration 55

5.2.1 Trial Duration by Stage of Development and Molecule Type 55

5.2.2 Trial Duration by Stage of Development and Molecular Target 56

5.3 Clinical Trial Size 57

5.3.1 Patient Enrollment per Product by Stage of Development and Molecule Type/Molecular Target 57

5.3.2 Patient Enrollment per Trial by Stage of Development and Molecule Type/Molecular Target 59

5.4 Summary of Clinical Trial Metrics 61

6 Multi-Scenario Forecast 63

6.1 Geographical Markets 63

6.2 South-East Asia Markets 63

6.3 South Korea 66

6.3.1 Treatment Usage Patterns 66

6.3.2 Annual Cost of Therapy 66

6.3.3 Market Size 67

6.4 Singapore 68

6.4.1 Treatment Usage Patterns 68

6.4.2 Annual Cost of Therapy 69

6.4.3 Market Size 69

6.5 Taiwan 70

6.5.1 Treatment Usage Patterns 70

6.5.2 Annual Cost of Therapy 71

6.5.3 Market Size 72

6.6 Malaysia 73

6.6.1 Treatment Usage Patterns 73

6.6.2 Annual Cost of Therapy 74

6.6.3 Market Size 75

6.7 Philippines 76

6.7.1 Treatment Usage Patterns 76

6.7.2 Annual Cost of Therapy 77

6.7.3 Market Size 78

6.8 Thailand 79

6.8.1 Treatment Usage Patterns 79

6.8.2 Annual Cost of Therapy 80

6.8.3 Market Size 81

6.9 Vietnam 82

6.9.1 Treatment Usage Patterns 82

6.9.2 Annual Cost of Therapy 83

6.9.3 Market Size 84

6.10 Indonesia 85

6.10.1 Treatment Usage Patterns 85

6.10.2 Annual Cost of Therapy 86

6.10.3 Market Size 87

6.11 Market Dynamics (Drivers and Barriers) 88

6.11.1 Drivers 88

6.11.2 Barriers 89

7 Deals and Strategic Consolidations 90

7.1 Licensing Deals 90

7.1.1 Deals by Region and Value 90

7.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 92

7.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target 92

7.1.4 Mylan Enters into Licensing Agreement with Momenta Pharmaceuticals for Biosimilar Candidates 95

7.1.5 Roche Enters into Licensing Agreement with Proximagen for VAP-1 Inhibitor 95

7.1.6 Alder Biopharmaceuticals Enters into Licensing Deal with Bristol-Myers Squibb and Alder Biopharmaceuticals for Clazakizumab 96

7.1.7 Ablynx Enters into a Licensing Deal with AbbVie for the Nanobody ALX-0061 96

7.2 Co-development 97

7.2.1 Deals by Region and Value 97

7.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 98

7.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 99

7.2.4 Gilead Sciences Enters into Co-development Agreement with Galapagos 102

7.2.5 Nextera Enters into Research Agreement with Janssen Biotech 103

7.2.6 GlaxoSmithKline Enters into Global Agreement with Archemix 103

7.2.7 Chroma Therapeutics Enters into Co-development Agreement with GlaxoSmithKline 103

8 Appendix 105

8.1 All Pipeline Drugs by Stage of Development 105

8.1.1 Discovery 105

8.1.2 Preclinical 108

8.1.3 IND/CTA-filed 117

8.1.4 Phase I 118

8.1.5 Phase II 120

8.1.6 Phase III 122

8.1.7 Pre-registration 123

8.2 Summary of Multi-Scenario Market Forecasts to 2022 123

8.3 Abbreviations 127

8.4 References 129

8.5 Research Methodology 136

8.5.1 Secondary Research 137

8.5.2 Marketed Product Profiles 137

8.5.3 Late-Stage Pipeline Candidates 137

8.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products 137

8.5.5 Pipeline Analysis 138

8.5.6 Forecasting Model 139

8.5.7 Deals Data Analysis 140

8.6 Contact Us 140

8.7 Disclaimer 140


List of Tables

Table 1: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010–2013 18

Table 2: Breast Cancer Therapeutics, Southeast Asia, Five-year Survival Rate (%) 19

Table 3: Breast Cancer Therapeutics Market, Global, Licensing Deals in Southeast Asia and Deals with Disclosed Values, 2006–2016 110

Table 4: Breast Cancer Therapeutics Market, Global, Co-development Deals in Southeast Asia and Deals with Disclosed Values, 2006–2016 117

Table 5: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Discovery, 2016 118

Table 6: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, IND/CTA- filed, 2016 124

Table 7: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016 125

Table 8: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase I, 2016 146

Table 9: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase II, 2016 152

Table 10: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase III, 2016 158

Table 11: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2016 159

Table 12: Breast Cancer Therapeutics Market, Southeast Asia, Market Forecast, 2015–2022 160

Table 13: Breast Cancer Therapeutics Market, South Korea, Market Forecast, 2015–2022 160

Table 14: Breast Cancer Therapeutics Market, Singapore, Market Forecast, 2015–2022 160

Table 15: Breast Cancer Therapeutics Market, Taiwan, Market Forecast, 2015–2022 161

Table 16: Breast Cancer Therapeutics Market, Malaysia, Market Forecast, 2015–2022 161

Table 17: Breast Cancer Therapeutics Market, Philippines, Market Forecast, 2015–2022 161

Table 18: Breast Cancer Therapeutics Market, Thailand, Market Forecast, 2015–2022 162

Table 19: Breast Cancer Therapeutics Market, Vietnam, Market Forecast, 2015–2022 162

Table 20: Breast Cancer Therapeutics Market, Indonesia, Market Forecast, 2015–2022 162


List of Figures

Figure 1: Breast Cancer Therapeutics, Southeast Asia, Age-Standardized Incidence (per 100,000 population), 2012 12

Figure 2: Breast Cancer Therapeutics, South Korea, Age-Specific Incidence (%), 2012 13

Figure 3: Breast Cancer Therapeutics, Southeast Asia, Age-Standardized Mortality (per 100,000 population), 2012 14

Figure 4: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I–III 24

Figure 5: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV 25

Figure 6: Breast Cancer Therapeutics Market, Global, Heatmap, 2017 34

Figure 7: Breast Cancer Therapeutics Market, Global, Overview of Pipeline Products 41

Figure 8: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline 43

Figure 9: Breast Cancer Therapeutics Market, Southeast Asia, Lynparza, Market Forecast ($m), 2020–2022 44

Figure 10: Breast Cancer Therapeutics Market, Southeast Asia, Veliparib, Market Forecast ($m), 2020–2022 46

Figure 11: Breast Cancer Therapeutics Market, Southeast Asia, Neratinib, Market Forecast ($m), 2020–2022 47

Figure 12: Breast Cancer Therapeutics Market, Southeast Asia, Pembrolizumab, Market Forecast ($m), 2019–2022 48

Figure 13: Breast Cancer Therapeutics Market, Southeast Asia, Ribociclib, Market Forecast ($m), 2020–2022 50

Figure 14: Breast Cancer Therapeutics Market, Southeast Asia, Alpelisib, Market Forecast ($m), 2020–2022 51

Figure 15: Breast Cancer Therapeutics Market, Southeast Asia, Taselisib, Market Forecast ($m), 2020–2022 53

Figure 16: Breast Cancer Therapeutics Market, Southeast Asia, Vinflunine, Market Forecast ($m), 2018–2022 55

Figure 17: Breast Cancer Therapeutics Market, Global, Pipeline Heatmap, 2017 62

Figure 18: Breast Cancer Therapeutics Market, Competitor Matrix for Breast Cancer Marketed and Pipeline Products, 2017 63

Figure 19: Breast Cancer Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2006–2016 65

Figure 20: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006–2016 66

Figure 21: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006–2016 67

Figure 22: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 68

Figure 23: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016 69

Figure 24: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2016 70

Figure 25: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecular target (participants), 2006–2016 71

Figure 26: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006–2016 72

Figure 27: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006–2016 73

Figure 28: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 74

Figure 29: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 74

Figure 30: Breast Cancer Therapeutics Market, Southeast Asia, Treatment Usage Pattern (‘000), 2015–2022 76

Figure 31: Breast Cancer Therapeutics Market, Southeast Asia, Market Size ($bn), 2015–2022 77

Figure 32: Breast Cancer Therapeutics Market, South Korea, Treatment Usage Patterns (‘000), 2015–2022 78

Figure 33: Breast Cancer Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015–2022 79

Figure 34: Breast Cancer Therapeutics Market, South Korea, Market Size ($m), 2015–2022 80

Figure 35: Breast Cancer Therapeutics Market, Singapore, Treatment Usage Patterns (‘000), 2015–2022 81

Figure 36: Breast Cancer Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2015–2022 82

Figure 37: Breast Cancer Therapeutics Market, Singapore, Market Size ($m), 2015–2022 83

Figure 38: Breast Cancer Therapeutics Market, Taiwan, Treatment Usage Patterns (‘000), 2015–2022 84

Figure 39: Breast Cancer Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2015–2022 85

Figure 40: Breast Cancer Therapeutics Market, Taiwan, Market Size ($m), 2015–2022 86

Figure 41: Breast Cancer Therapeutics Market, Malaysia, Treatment Usage Patterns (‘000), 2015–2022 87

Figure 42: Breast Cancer Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2015–2022 88

Figure 43: Breast Cancer Therapeutics Market, Malaysia, Market Size ($m), 2015–2022 89

Figure 44: Breast Cancer Therapeutics Market, Philippines, Treatment Usage Patterns (‘000), 2015–2022 90

Figure 45: Breast Cancer Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2015–2022 91

Figure 46: Breast Cancer Therapeutics Market, Philippines, Market Size ($m), 2015–2022 92

Figure 47: Breast Cancer Therapeutics Market, Thailand, Treatment Usage Patterns (‘000), 2015–2022 93

Figure 48: Breast Cancer Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2015–2022 94

Figure 49: Breast Cancer Therapeutics Market, Thailand, Market Size ($m), 2015–2022 95

Figure 50: Breast Cancer Therapeutics Market, Vietnam, Treatment Usage Patterns (‘000), 2015–2022 96

Figure 51: Breast Cancer Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2015–2022 97

Figure 52: Breast Cancer Therapeutics Market, Vietnam, Market Size ($m), 2015–2022 98

Figure 53: Breast Cancer Therapeutics Market, Indonesia, Treatment Usage Patterns (‘000), 2015–2022 99

Figure 54: Breast Cancer Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2015–2022 100

Figure 55: Breast Cancer Therapeutics Market, Indonesia, Market Size ($m), 2015–2022 101

Figure 56: Breast Cancer Therapeutics Market, Global, Licensing Deals by Region and Value, 2006–2016 105

Figure 57: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2016 106

Figure 58: Breast Cancer Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2016 107

Figure 59: Breast Cancer Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006–2016 108

Figure 60: Breast Cancer Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006–2016 109

Figure 61: Breast Cancer Therapeutics Market, Global, Co-development Deals by Region, 2006–2016 113

Figure 62: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2016 114

Figure 63: Breast Cancer Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006–2016 114

Figure 64: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006–2016 115

Figure 65: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006–2016 116

Title Date Price
Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report
By QYResearch
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry. The re ...Read More
Apr 2016 $3600.00
Global Dental Laboratory Handpieces Consumption 2016 Market Research Report
By QYResearch
The Global Dental Laboratory Handpieces Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Dental Laboratory Handpieces market. First, the report ...Read More
Jan 2016 $4000.00
Back to Report Store Home Cardiovascular Disorders Drug Development Pipeline Review, 2017
By GBI Research
Description Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dys ...Read More
Mar 2017 $3995.00
Back to Report Store Home Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes
By GBI Research
Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain ...Read More
Aug 2016 $6995.00
Back to Report Store Home Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation
By GBI Research
Description Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare a ...Read More
Jun 2017 $6995.00
Back to Report Store Home Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need
By GBI Research
The hematological disorders therapy area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. These diseases can be grouped into the three ...Read More
Aug 2017 $6995.00
Back to Report Store Home Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation
By GBI Research
Description Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related death (Globocan, 2012). Currently, the range of therapi ...Read More
Jun 2017 $6995.00
Back to Report Store Home Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation
By GBI Research
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a ...Read More
Aug 2016 $6995.00
Back to Report Store Home Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential
By GBI Research
Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or a ...Read More
Jan 2017 $6995.00
Back to Report Store Home Global Immunology Drugs Market to 2022-Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth
By GBI Research
Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation ...Read More
May 2017 $4995.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

Published By :  GBI Research

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z